Dermapharm Holding SE : FY 2022 guidance as we expected, but not as the consensus expected
>Guiding for 3-7% y-o-y adj. EBITDA growth for FY 2022 - Dermapharm today issued its FY 2022 guidance after having already released prelims last week. The company guides for revenue growth of 10-13% y-o-y and adj. EBITDA growth of 3-7% y-o-y. While we are looking for 9% y-o-y revenue growth in FY 2022, i.e. below the company guidance, our adj. EBITDA forecast sees 6.5% y-o-y growth. This is the higher end of guidance. While we acknowledge that our FY 2021 forecast was...Dermapharm Holding SE. Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.